Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Bromhexine  COVID-19 treatment studies for Bromhexine  C19 studies: Bromhexine  Bromhexine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 45% Improvement Relative Risk Recovery time 15% Ghayour et al. IRCT20220302054167N1 Bromhexine RCT EARLY Is early treatment with bromhexine beneficial for COVID-19? RCT 150 patients in Iran (April - September 2022) Trial compares with NAC, results vs. placebo may differ Lower hospitalization (p=0.3) and faster recovery (p=0.094), not stat. sig. Ghayour et al., Research Square, doi:10.21203/ Favors bromhexine Favors NAC
Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized clinical trial comparing N-acetylcysteine with Bromhexine
Ghayour et al., Research Square, doi:10.21203/ (Preprint), IRCT20220302054167N1
Ghayour et al., Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized.., Research Square, doi:10.21203/ (Preprint), IRCT20220302054167N1
Jan 2023   Source   PDF  
  All Studies   Meta
RCT 150 outpatients in Iran comparing N-acetylcysteine and bromhexine, showing lower hospitalization and faster recovery with bromhexine, without statistical significance. Baseline information per group is not provided, and Figure 1 appears to have the two groups switched and an incorrect value for the not hospitalized total in one group. N-acetylcysteine 600mg daily for 5 days, bromhexine 8mg tid for 5 days.
Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion. This study is excluded in the after exclusion results of meta analysis: results unclear due to errors in the preprint, baseline group details not provided.
risk of hospitalization, 45.5% lower, RR 0.55, p = 0.30, treatment 6 of 75 (8.0%), control 11 of 75 (14.7%), NNT 15.
recovery time, 14.9% lower, relative time 0.85, p = 0.09, treatment 75, control 75.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ghayour et al., 3 Jan 2023, Randomized Controlled Trial, Iran, preprint, mean age 58.6, 4 authors, study period April 2022 - September 2022, this trial compares with another treatment - results may be better when compared to placebo, trial IRCT20220302054167N1.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBromhexineAll
Abstract: Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized clinical trial comparing Nacetylcysteine with Bromhexine Anahita Eslami Ghayour (  ) Hamedan University of medical science Sasan Nazari Hamedan University of medical science Fariba Keramat Hamedan University of medical science Fatemeh Shahbazi Hamedan University of medical science Research Article Keywords: COVID-19, N-acetylcysteine, Bromhexine, Infection diseases Posted Date: January 3rd, 2023 DOI: License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/12 Abstract Objectives: Due to the referral of COVID-19 patients to outpatient centers in the early stages, the aim of the present study is to compare the effect of N-acetylcysteine and Bromhexine on the recovery rate and prevention of hospitalization in outpatients with COVID-19 Methodology: This study was conducted from April 2022 to September 2022. First, PCR-confirmed COVID-19 patients were divided into two groups, one of these groups received N-acetylcysteine while the other received bromhexine. The patients were followed up on the seventh and fourteenth days of the disease in terms of the duration of changes in oxygen saturation and recovery. The hospitalization and death of the patients were also evaluated after one month. Results: Out of 150 studied patients, oxygen saturation was increased by 1.33% in the third visit of the patients who received N-acetylcysteine compared to their first visit. This percentage was 1.19% in the patients who received bromhexine.11.33% of the patients were admitted to the hospital and 88.6% of them had no history of hospitalization within 14 day and their mortality rate was zero. Conclusions: The results of this study showed that early initiation of Bromhexine can effectively reduce the hospitalization rate and shorten the duration of hospitalization. Clinical trial code: IRCT20220302054167N1 and ethics code: IR.UMSHA.REC.1400.957
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop